CXCL9 and neoplasm: Epigenetic reprogramming can sensitize cancer cells to immune checkpoints blocking therapies through the upregulation of immunostimulatory cytokines (e.g. CXCL9 and CXCL10) that recruit T lymphocytes to the tumor site [17, 42].